Drugs / sodium chlorite
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02794857 | Aug 2016 → Dec 2017 | amyotrophic lateral sclerosis | Neuraltus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT00947362 | Aug 2004 → Dec 2007 | — | Waisenmedizin e. V. Promoting Access to Essential Medicine | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sodium chlorite | “daily moist-wound-treatment (MWT) with polyacrylate hydrogel with (group I) or without (group II) pharmaceutical sodium chlorite (DAC N-055)” PMID 24551257 ↗ Feb 20141“the innate immune modulator NP001 (a pH-adjusted intravenous formulation of purified sodium chlorite)” PMID 39457678 ↗ Oct 2024 |
| Known as | DAC N-055 | “daily moist-wound-treatment (MWT) with polyacrylate hydrogel with (group I) or without (group II) pharmaceutical sodium chlorite (DAC N-055)” PMID 24551257 ↗ Feb 2014 |
| Known as | NP001 | “the innate immune modulator NP001 (a pH-adjusted intravenous formulation of purified sodium chlorite)” PMID 39457678 ↗ Oct 2024 |
| Route | Topical | “The skin lesions were treated with bipolar high-frequency electrocauterization (EC) followed by daily moist-wound-treatment (MWT) with polyacrylate hydrogel with (group I) or...” PMID 24551257 ↗ Feb 2014 |